Zacks Investment Research on MSN
REGN soars 41% in six months: Is there more upside potential in 2026?
The going has been strong for Regeneron Pharmaceuticals REGN over the past six months. Shares of this biotech giant have ...
Sanofi (NASDAQ:SNY) said on December 15 that a US regulatory decision for its experimental multiple sclerosis drug will be ...
On December 12, Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron Pharmaceuticals, Inc.
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...
In March 2025, Japan’s Ministry of Health, Labour and Welfare has approved the marketing and manufacturing of Dupixent ...
Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...
Sanofi has announced that Paul Hudson, CEO, will be in attendance at the 44 th annual JP Morgan Healthcare Conference in San ...
The deal gives Sanofi access to Dynavax’s approved hepatitis B vaccine, News.Az reports, citing Reuters. This acquisition ...
Sanofi agreed to buy vaccine specialist Dynavax Technologies in a $2.2 billion cash deal, turning to dealmaking in a bid to move past pipeline setbacks.
Sanofi will buy U.S. vaccines company Dynavax Technologies for around $2.2 billion (1.9 billion euros), expanding its ...
Sanofi and Regeneron receives Japanese marketing approval for Dupixent to treat bronchial asthma in children aged 6 to 11 years: Paris Wednesday, December 24, 2025, 11:00 Hrs [IST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback